GlassScriptPhysician profile
Gene Gerlach
NPI 1316680226
$1,213.92
in general payments reported to CMS, 2019-2025
10 companies · $743 in 2025
The $743 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.76 · 2023: $120 · 2024: $338 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728 · Education: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.37 |
| Education | $472.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $567.55 | 2025 | Resolute Onyx, Ffrangio |
| Esperion Therapeutics, INC. | $122.56 | 2024 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $105.97 | 2022-2025 | Andexxa |
| Daiichi Sankyo INC. | $100.25 | 2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $78.77 | 2023 | Terlivaz |
| Novo Nordisk INC | $76.34 | 2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $66.15 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $58.87 | 2023-2025 | Verquvo |
| Averitas Pharma INC. | $19.26 | 2023 | Qutenza |
| Boston Scientific Corporation | $18.20 | 2025 | Accolade Sr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Gerlach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.